Scientist, In Vitro Biology

About Us

aTyr is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to downregulate immune engagement in fibrotic lung disease. aTyr is publicly traded on Nasdaq under the symbol “LIFE”. For more information, please visit


Patients and their challenges provide tremendous drive and meaning to what we do at aTyr. We seek a talented and successful individual that deeply desires to participate in our process to make medicines that change a patient’s life forever.

Primary Responsibilities

We are seeking to add an enthusiastic and highly motivated researcher to our team focusing on the development of novel medicines based on our research into new biological pathways. In this position, you will play an important role in the discovery and development of new drug candidates through your expertise and work in cell biology. Candidates with expertise in fibrosis and fibrotic diseases are highly encouraged to apply. You will design, execute and analyze complex experiments, especially cell-based assays. You will need to summarize and present the results of your experiments to the research team.


The role requires the ability to collaborate with colleagues in a cross-functional, intensely fast-paced team environment. The successful candidate will be self-motivated, resourceful, and flexible with the ability to handle rapidly changing objectives and timelines. Extensive experience working with cells in culture as well as cell-based assays is required.

The ideal candidate will have:

  • PhD degree in biochemistry/biological sciences or a related discipline with 0-3 years of postgraduate experience
  • Strong background in cell biology, including cell signaling
  • Training in fibrosis and fibrotic disease models is highly desired
  • Extensive experience with culture of mammalian cells and cell-based assays
  • Should be able to work with minimal supervision and a high level of initiative
  • Strong analytical skills and problem solving ability
  • Strong verbal and written communication skills
  • Immediate availability is advantageous

Further Recruiting Information

For additional information about aTyr Pharma, please visit our website at aTyr Pharma, Inc. is an EEO employer.

The salary range for this position is $100,000 USD to $130,000 USD annually. This salary range is an estimate, and the actual salary may vary based on the Company’s compensation practices. In addition to a competitive compensation package with stock options and an Employee Stock Purchase Plan, aTyr Pharma also offers a comprehensive benefits package for our employees and their families, which includes medical, dental, life, disability and a 401(k)-matching contribution.

For consideration, please submit your resume and cover letter referencing job #212RA to


Testing display of HTML elements – h1 tag

This is a test paragraph.

This is 2nd level heading – h2 tag

This is a test paragraph.

This is 3rd level heading – h3 tag

This is a test paragraph.

This is 3rd level heading – h3 tag with class .even

This is 3rd level heading – h3 tag with class .odd

This is 4th level heading – h4 tag

This is a test paragraph.

This is 5th level heading

This is a test paragraph.

This is 6th level heading

This is a test paragraph.

Basic block level elements

This is the caption for the image
This is the caption for the image

TOGETHER WE believe that MicroRNA therapeutics will become a major new class of drugs. We are focused on harnessing their power to target multiple pathways of disease.

This is a normal paragraph. To add some length to it, let us mention that this page was primarily written for testing the effect of user style sheets. You can use it for various other purposes as well, like just checking how your browser displays various HTML elements by default. It can also be useful when testing conversions from HTML format to other formats, since some elements can go wrong then. Dysregulated microRNA expression is a key factor in many complex multi-factoral diseases, including inflammatory disease, fibrosis, metabolic disease and cancer. microRNA therapeutics are oligonucleotides that modulate the function of microRNAs, correcting the imbalance of gene expression and associated cellular pathways to treat a broad range human disease.This is another paragraph. I think it needs to be added that the set of elements tested is not exhaustive in any sense.

Balboa Park 1915 caption
Balboa Park 1915 caption

microRNAs are members of a large class of non-coding RNAs of approximately 22 nucleotides in length that regulate most genes in the genome. A single microRNA can target and regulate up to hundreds of genes and these genes are involved in biological networks or pathways.I have selected those elements for which it can make sense to write user style sheet rules, in my opinion.

Together, the Regulus team is leading the way in the discovery and development of microRNA therapeutics.

Regulus was formed in September 2007 by Alnylam Pharmaceuticals (NASDAQ:ALNY) and Isis Pharmaceuticals, now Ionis Pharmaceuticals (NASDAQ:IONS) and has continued to build upon our thought leadership, knowledge base, intellectual property and a clear focus to become the leader in microRNA therapeutics. The Regulus systems approach has mapped more than 6,000 diseases to specific tissue pathologies as well as their driver genes. It has linked specific microRNAs to the regulation of those driver genes and tissue disease states. Regulus has benefited from the collective therapeutic RNA expertise of its founding companies, including established proprietary oligonucleotide-based technologies, and broad and dominant intellectual property estates specific to chemically modified oligonucleotides. Regulus can access over 850 patents and patent applications in oligonucleotide technologies as well as owning over 200 patents and patent applications directed to microRNA delivery, manufacturing and specific technologies.

This is a block quotation containing a single paragraph. Well, not quite, since this is not really quoted text, but I hope you understand the point. After all, this page does not use HTML markup very normally anyway.

Regulus Therapeutics is located in La Jolla, California and is led by a seasoned executive team and board of directors, with proven expertise in corporate management, business operations, drug discovery, development and commercialization.


  • One.
  • Two.
  • Three. Well, probably this list item should be longer. Note that for short items lists look better if they are compactly presented, whereas for long items, it would be better to have more vertical spacing between items.
  • Four. This is the last item in this list. Let us terminate the list now without making any more fuss about it.

lorum ipsum text here to show odd

lorem upsum to show even

This is a paragraph before a numbered list (ol). Note that the spacing between a paragraph and a list before or after that is hard to tune in a user style sheet. You can””t guess which paragraphs are logically related to a list, e.g. as a “list header”.

  1. One.
  2. Two.
  3. Three. Well, probably this list item should be longer. Note that if items are short, lists look better if they are compactly presented, whereas for long items, it would be better to have more vertical spacing between items.
  4. Four. This is the last item in this list. Let us terminate the list now without making any more fuss about it.


This is a text paragraph that contains some inline links. Generally, inline links (as opposite to e.g. links lists) are problematic from the usability perspective, but they may have use as “incidental”, less relevant links. See the document Links Want To Be Links.



The following table has a caption. The first column contain table header cells (th elements) only; other cells are data cells with even/odd classes.

Sample table: Areas of the Nordic countries, in sq km
Country Total area Land area
Denmark 43,070 42,370
Finland 337,030 305,470
Iceland 103,000 100,250
Norway 324,220 307,860
Sweden 449,964 410,928
© 2007 - 2023   aTyr Pharma.   Legal   Privacy Policy